Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,
Tag: SBECD
Summary of currently available drugs which can be potentially used for treatment of COVID-19
The Table below was published in e-book International Pulmonologist’s Consensus On Covid-19 2nd ed 2020 on April 22nd 2020 (ed. Tinku
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
A new country to approve remdesivir for COVID-19 treatment: Israel
Israel approved on Tuesday the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients with COVID-19
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
Conditional approval of Veklury® (SBECD-enabled remdesivir) for COVID-19 infection in Singapore
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
Use of cyclodextrins as agrochemical delivery system
ADAMA MAKHTESHIM LTD. (Israel) filed a PCT patent application (WO2020084572) that was recently published. The invention relates to preparation and use
ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus